What did Leerink change in the VIR analyst rating on February 26, 2026?

Leerink maintained an **Outperform** rating and raised the price target to **$20** on February 26, 2026. The firm kept its positive stance while updating valuation assumptions.

How should investors interpret a maintained Outperform for Vir Biotechnology, Inc.?

A maintained Outperform means the analyst still expects outperformance versus peers. Investors should see continued confidence, but monitor financing and clinical catalysts for risk.

Does the VIR analyst rating affect the stock price immediately?

Ratings can move prices, but this note produced a modest **2.21% ($0.21)** change. Broader news like offerings or partnerships often drives larger moves.

What is Meyka AI’s current view on Vir Biotechnology, Inc.?

Meyka AI rates **VIR with a grade of B**, considering market benchmarks, sector trends, financial growth, and analyst consensus. This is informational and not financial advice.

Analyst Ratings

Leerink Maintains Outperform on Vir Biotechnology, Inc. (VIR) Feb 2026

ByDanny Kontos February 27, 2026February 27, 2026

Leerink Partners on February 26, 2026 maintained an Outperform rating on Vir Biotechnology, Inc. (VIR), while raising the price target to $20. The move is logged as a maintained positive stance, not a formal upgrade or downgrade, and it arrives amid recent company financing and partnership news. This update is relevant to traders tracking momentum and long-term investors assessing analyst conviction. The phrase VIR analyst rating signals the market view that Leerink still favors the stock while adjusting its earnings outlook and target.